LPLisa Peyrard

Lisa Peyrard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lisa Peyrard has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Anne-Laure Larroque

    The Research Institute of the McGill University Health Center, Montreal, QC H4A 3J1, Canada

    1 shared publication
  • Benoît Thibault

    CRCT, Université de Toulouse, Inserm, CNRS, UJniversité Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France

    1 shared publication
  • Bertrand J. Jean-Claude

    Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University/Royal Victoria Hospital, Montreal, Quebec, Canada and

    1 shared publication
  • Cédric Thauvin

    Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada

    1 shared publication
  • Martin Rupp

    Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada

    1 shared publication
  • Suman Rao

    Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada

    1 shared publication

Latest Publications

  • Open Access

    Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting

    by Suman Rao, Benoît Thibault, Lisa Peyrard, Anne-Laure Larroque-Lombard, Martin Rupp, Cédric Thauvin, Bertrand J. Jean-Claude

    The median-effect principle proposed by Chou and Talalay is the most effective approach to parameterize interactions between several agents in combination. However, this method cannot be used to evaluate the effectiveness of equimolar drug combinations, which are comparative references for dual-targeting molecular design. Here, using data acquired through the development of “combi-molecules” blocking two kinases (e.g., EGFR-c-Src and EGFR-c-Met), we established potency indices for equimolar and dual-targeted inhibitors. If the fold difference (κ) between the IC50 of the two individual kinase inhibitors was >6, the IC50 of their equimolar combination resembled that of the more potent inhibitor. Hence, the “combi-targeting” of the two kinases was considered “imbalanced” and the combination ineffective. However, if κ ≤ 6, the IC50 of the combination fell below that of each individual drug and the combi-targeting was considered “balanced” and the combination effective. We also showed that combi-molecules should be compared with equimolar combinations only under balanced conditions and propose a new parameter Ω for validating their effectiveness. A multi-targeted drug is effective if Ω < 1, where Ω is defined as the IC50 of the drug divided by that of the corresponding equimolar combination. Our study provides a methodology to determine the in vitro potency of equimolar two-drug combinations as well as combi-/hybrid molecules inhibiting two different kinase targets.